Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma Presented ByProf. Won-Seog Kim, Samsung Medical Center, South Korea TrialPhase 2, ELM-2 trial ConferenceASH 2022 20 February, 2023 12:30